Trial intelligence / Profile preview

Compassionate use of bevacizumab in chemotherapy-naive inoperable malignant pleural mesothelioma

jRCT2080223406Phase 3

Sponsor
Chugai Pharmaceutical Co., Ltd.
Start
Dec 2016
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of bevacizumab in pleural mesothelioma, sponsored by Chugai Pharmaceutical Co., Ltd.

02

Drugs

bevacizumab
03

Conditions

pleural mesothelioma

Beyond the preview

Go deeper on jRCT2080223406.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080223406.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call